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Abstract Although neurokinin A (NKA), a tachykinin peptide
with sequence homology to substance P (SP), is a weak
competitor of radiolabeled SP binding to the NK-1 receptor
(NK-1R), more recent direct binding studies using radiolabeled
NKA have demonstrated an unexpected high-affinity interaction
with this receptor. To document the site of interaction between
NKA and the NK-1R, we have used a photoreactive analogue of
NKA containing p-benzoyl-L-phenylalanine (Bpa) substituted in
position 7 of the peptide. Peptide mapping studies of the receptor
photolabeled by 125I-iodohistidyl1-Bpa7NKA have established
that the site of photoinsertion is located within a segment of the
receptor extending from residues 178 to 190 (VVCMIEW-
PEHPNR). We have previously shown that 125I-BH-Bpa8SP, a
photoreactive analogue of SP, covalently attaches to M181 within
this same receptor sequence. Importantly, both of these peptides
(125I-iodohistidyl1-Bpa7NKA and 125I-BH-Bpa8SP) have the
photoreactive amino acid in an equivalent position within the
conserved tachykinin carboxyl-terminal tail. In this report, we
also show that site-directed mutagenesis of M181 to A181 in the
NK-1R results in a complete loss of photolabeling of both
peptides to this receptor site, indicating that the equivalent
position of SP and NKA, when bound to the NK-1R, contact the
same residue. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
Key words: Substance P; Neurokinin A; NK-1 receptor;
Photoa⁄nity labeling
1. Introduction
The tachykinins comprise a family of bioactive peptides
which are structurally characterized by the conserved C-ter-
minal sequence of -Phe-Xaa-Gly-Leu-Met-NH2 [1^5]1. Two
mammalian tachykinins are substance P (SP) (Arg-Pro-Lys-
Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) and neurokinin A
(NKA) (His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2)
[4^6]. The mRNAs encoding both SP and NKA arise from
tissue-speci¢c di¡erential RNA processing of the preprotachy-
kinin-A gene [7^9]; post-translational modi¢cation by endo-
proteases and C-terminus amidation of protein precursors
then yield the mature bioactive peptides.
The NK-1 receptor (NK-1R), the well-documented site of
action for SP, is an integral membrane protein belonging to
the rhodopsin-type family of G-protein coupled receptors [10^
12]. Competition binding assays using radiolabeled SP and the
NK-1R have shown that (i) SP binds with high a⁄nity to the
NK-1R and that (ii) NKA is a poor competitor for radio-
labeled SP binding [13]. Since NKA displaces SP binding to
the NK-1R only at high concentrations, the notion that NKA
might functionally interact with the NK-1R was not immedi-
ately entertained. Recently, however, functional assays and
direct binding studies using radiolabeled NKA have demon-
strated that NKA can interact with the NK-1R with high
a⁄nity to elicit biological responses [14,15], despite its relative
inability to compete for receptor binding with SP. The most
straightforward explanation for this phenomenon is that the
two peptides interact on the receptor at distinct sites. An
alternative explanation, however, is the existence of multiple
ligand^speci¢c receptor conformations. We have addressed
these issues directly by comparing the site of photoincorpora-
tion of a photoreactive analogue of NKA, 125I-iodohistidyl1-
(p-benzoyl-L-phenylalanine)7NKA (125I-Bpa7NKA), with that
for the corresponding photoreactive analogue of SP, 125I-
(N-succinimidyl-3[4-hydroxyphenyl]propionate)3-Bpa8SP (125I-
BH-Bpa8SP).
This study presents the ¢rst direct biochemical evidence for
an NKA/NK-1R interaction, and moreover shows that the
structurally conserved C-terminal sequences of both SP and
NKA interact with a common region of the NK-1R.
2. Materials and methods
2.1. Materials
Puri¢ed SP and NKA were purchased from Sigma. Bpa8SP was
synthesized as described previously [16], and Bpa7NKA was obtained
from Je¡ Kelly (Scripps Institute, San Diego, CA, USA). 125I-Bolton
Hunter (BH) reagent and 125I (each with speci¢c activities of 2200 Ci/
mmol) were obtained from NEN Life Sciences. SP and Bpa8SP were
radioiodinated by coupling the Lys3 reside O-NH2 group to the 125I-
BH reagent as described previously [16], generating 125I-BH-SP and
125I-BH-Bpa8SP, respectively. NKA and Bpa7NKA were radioiodi-
nated by coupling the His1 residue to the solid phase oxidant
1,3,4,6-tetrachloro-3K,6K-diphenylglycoluril (IODO-GEN0 iodination
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reagent, Pierce) in the presence of 125I, generating 125I-iodohistidyl1-
NKA (125I-NKA) and 125I-Bpa7NKA, respectively.
2.2. Cell culture and site-directed mutagenesis
Chinese hamster ovary (CHO) cells stably transfected with the
cDNA encoding a geneticin resistance gene and (i) the full-length
rat NK-1R (rNK-1R) [17], (ii) a site-directed rNK-1R mutant in
which M174 was substituted by alanine2 or (iii) a site-directed rNK-
1R mutant in which M181 was substituted by alanine were kindly
provided by Dr. J.E. Krause (Neurogen, Brandford, CT, USA). All
transfected CHO cells were maintained as monolayer cultures in K-
minimal essential medium (Gibco BRL Life Technologies) supple-
mented with 10% (v/v) Cool Calf1 2 (Sigma) and 1 mg/ml geneticin
(G-418 sulfate) (Gibco BRL Life Technologies), as described previ-
ously [18,19]. Cells were grown in an atmosphere of 95% air and 5%
CO2 at 37‡C, and were harvested for experiments using phosphate-
bu¡ered saline based enzyme free dissociation bu¡er (Specialty Me-
dia).
2.3. Equilibrium displacement competition assay
Transfected CHO cells were harvested as described above and re-
suspended in ice-cold KRH bu¡er (20 mM HEPES, 1 mM CaCl2, 2.2
mM MgCl2, 5 mM KCl, 120 mM NaCl, pH 7.4) supplemented with
6 mg/ml glucose and 0.6 mg/ml bovine serum albumin (BSA). Cells
were incubated for 2 h at 4‡C with the radiolabeled ligands 125I-BH-
SP or 125I-NKA, and binding was measured either alone or in the
presence of increasing concentrations of unlabeled inhibitor. In all
experiments, non-speci¢c 125I-BH-SP or 125I-NKA binding was de-
¢ned as binding in the presence of 1 WM unlabeled peptide. To sep-
arate bound ligand from free ligand, cells were ¢ltered after incuba-
tion through Whatman GF/C ¢lter paper (soakeds 2 h in 0.1%
polyethylenimine) and washed three times in ice-cold KRH bu¡er
(pH 7.4) with a Brandel Harvester apparatus. Bound radioactivity
on the ¢lters was quanti¢ed with Q-emission spectrometry. Competi-
tion assays were performed in triplicate and repeated at least three
times.
2.4. Photoa⁄nity labeling of transfected CHO cells and identi¢cation
of photolabeled receptors
Stably transfected CHO cells were photolabeled with 125I-BH-
Bpa8SP or 125I-Bpa7NKA using the procedure described previously
[18,19]. Transfected cells were harvested, pelleted and resuspended in
ice-cold KRH bu¡er (pH 7.4) supplemented with 6 mg/ml glucose, 0.6
mg/ml BSA, 3 Wg/ml chymostatin, 5 Wg/ml leupeptin and 30 Wg/ml
bacitracin. The cell resuspensions were then incubated in the dark
with 125I-BH-Bpa8SP (added to a ¢nal concentration of 0.5^1.0 nM)
or 125I-Bpa7NKA (added to a ¢nal concentration of 3.0^3.5 nM) for
2 h at 4‡C with gentle agitation. Competing peptides or non-peptide
antagonists were added at the concentrations indicated. Following
incubation, the mixtures were diluted 1:1 with ice-cold KRH bu¡er
(pH 7.4) and irradiated at 365 nm by exposure to a 100 W long-wave
UV lamp for 15 min at a distance of 6 cm. Cell membranes were then
prepared as described previously [18,19]. 125I-BH-Bpa8SP- or 125I-
Bpa7NKA-labeled membranes were next solubilized in sample bu¡er
(0.125 M Tris, 2% sodium dodecyl sulfate (SDS), 10% glycerol, 0.01%
bromophenol blue, pH 6.8), heated at 55‡C for 10 min, and then
subjected to SDS^polyacrylamide gel electrophoresis (PAGE) as de-
scribed by Laemmli [20].
The percent photoincorporation of 125I-BH-Bpa8SP or 125I-
Bpa7NKA into the wildtype (WT), M174A and M181A rNK-1Rs
was determined as described previously [16] by comparing the amount
of photoligand incorporated into the receptors after UV exposure (as
determined by SDS^PAGE resolution, autoradiography and Q-emis-
sion spectrometric analysis) to the amount of photoligand speci¢cally
bound to the receptors before UV exposure (as determined by equi-
librium ¢ltration binding assay).
2.5. Tryptic digestion of photolabeled receptors
125I-BH-Bpa8SP- or 125I-Bpa7NKA-labeled membranes were resus-
pended in 0.1% SDS, 50 mM Tris, 1 mM CaCl2, pH 8.0, and digested
at room temperature for 2 h with 0.02 mg/ml L-1-tosylamide-2-phenyl-
ethylchloromethyl ketone-treated bovine trypsin (Sigma). NK-p-tosyl-
L-lysine chloromethyl ketone was added to the reaction mixtures in a
1:1000 dilution following incubation to terminate enzymatic activity.
Sample bu¡er ( þ 30 mM D,L-dithiothreitol, DTT) was then added to
the samples. The mixtures ( þ 30 mM DTT) were allowed to incubate
for 1 h at room temperature before being heated for 10 min at 55‡C,
as described above. Tryptic cleavage fragments were separated and
analyzed using the tricine-gel system of SDS^PAGE [21].
3. Results
3.1. A⁄nity of photoreactive tachykinin analogues for the
NK-1R as measured by homologous and heterologous
competition binding assays
To gain information on the bimolecular complexes formed
between SP and the NK-1R as well as NKA and the NK-1R,
a photoreactive analogue of each peptide was synthesized
(Bpa8SP and Bpa7NKA, respectively) (Fig. 1). Importantly,
the introduction of the photoreactive Bpa residue into either
the eighth position of SP (normally a Phe) or the seventh
position of NKA (normally a Val) does not signi¢cantly alter
the receptor binding characteristics of these tachykinin ana-
logues, making them useful for direct receptor photolabeling
experiments. Both Bpa8SP and Bpa7NKA also elicit a calcium
response from rNK-1R-expressing CHO cells (data not
shown), consistent with their being functional agonists at
this receptor. Therefore, since Bpa8SP and Bpa7NKA bind
the NK-1R in a manner indistinguishable from that of SP
and NKA, respectively, the introduction of the Bpa residue
into the photoreactive tachykinin analogues does not signi¢-
cantly alter the functional properties of the ligands.
3.2. 125I-Bpa7NKA speci¢cally photolabels the NK-1R
Our laboratory has successfully used Bpa8SP as an e⁄cient
photoreactive ligand for the rNK-1R [18,22]; moreover, a
radiolabeled derivative of Bpa8SP, 125I-BH-Bpa8SP, has
been used to identify M181 as a site of covalent attachment
of SP to the rNK-1R [19]. In this report, we show that the
Table 1
Average IC50 values for rNK-1R ligands
Competing ligand 125I-BH-SP binding IC50 (nM þ S.E.M.) 125I-NKA binding IC50 (nM þ S.E.M.)
SP 0.9 þ 0.3 0.09 þ 0.02
Bpa8SP 1 þ 0.3 0.1 þ 0.03
NKA 46 þ 4 5 þ 2
Bpa7NKA 48 þ 4 6 þ 2
Fig. 1. Amino acid sequences of Bpa8SP and Bpa7NKA. Note that
the Bpa residue of both Bpa8SP and Bpa7NKA is located in an
equivalent position within the conserved tachykinin C-terminal tail.
2
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tachykinin derivative Bpa7NKA is also a high-a⁄nity ligand
for the rNK-1R (Table 1), and that its radiolabeled derivative,
125I-Bpa7NKA, speci¢cally photolabels the rNK-1R as well
(Fig. 2). Pharmacological evidence of the speci¢city of the
125I-BH-Bpa8SP^rNK-1 and 125I-Bpa7NKA^rNK-1R interac-
tion is provided by results showing that the addition of 1 WM
SP, NKA or RP 67 580 (a rNK-1R non-peptide antagonist
[23]) prevents rNK-1R labeling by both 125I-BH-Bpa8SP and
125I-Bpa7NKA, whereas the addition of 1 WM of SR 48 968 (a
rNK-2R non-peptide antagonist [24]) has no e¡ect on receptor
photolabeling.
3.3. 125I-Bpa7NKA photolabels the same residue on the NK-1R
as 125I-BH-Bpa8SP
Since the seventh amino acid of NKA is in the equivalent
position as the eighth amino acid of SP (Fig. 1), the use of
Bpa7NKA as a photoligand is strategic in that it allows direct
comparison of 125I-Bpa7NKA^rNK-1R peptide mapping data
with the published results of extensive peptide mapping stud-
ies performed on the 125I-BH-Bpa8SP-labeled rNK-1R
[18,19,22]. In the absence of DTT, trypsinization of the 125I-
BH-Bpa8SP-labeled rNK-1R results in the generation of two
receptor fragments linked by a disul¢de bond between C105
and C180, with a combined MrV8 kDa. Reduction with DTT
yields a smaller fragment (MrV3 kDa) that contains residues
178^190 of the NK-1R second extracellular (E2) loop. Large-
scale isolation of this particular V3 kDa rNK-1R fragment
and characterization by matrix-assisted laser desorption ion-
ization (MALDI) mass spectrometry has identi¢ed the residue
within this sequence that serves as the site of covalent attach-
ment of 125I-BH-Bpa8SP to the rNK-1R as M181 [19].
Peptide mapping studies performed on the 125I-Bpa7NKA-
labeled rNK-1R show a remarkable similarity to those dis-
cussed above for the 125I-BH-Bpa8SP-labeled rNK-1R, i.e.
the generation of a fragment at MrV8 kDa following trypsi-
nization, which is reduced in size to MrV3 kDa following
reduction with DTT (Fig. 3). These data suggest that the
site of covalent attachment of 125I-Bpa7NKA to the rNK-
1R is also to a residue in the MrV3 kDa fragment of the
E2 loop extending from residues 178^190.
To test whether 125I-Bpa7NKA speci¢cally photolabels
rNK-1R residue M181, photolabeling experiments using mu-
tant rNK-1Rs were performed (Fig. 4). Two speci¢c mutant
rNK-1Rs, in which an alanine residue is substituted for either
M174 (M174A) or M181 (M181A), have been characterized
(Table 2) and are both functional. These two mutant receptors
were constructed on the basis of M181 serving as the site of
photoinsertion of 125I-BH-Bpa8SP to the rNK-1R [19], and
M174 serving as the site of photoinsertion of another photo-
reactive SP analogue designed in our laboratory, 125I-BH-
Bpa4SP, to the rNK-1R [25]. In this report, we show that
when alanine is substituted for M181, although 125I-BH-
Bpa8SP binding is not signi¢cantly a¡ected (IC50 values of
0.77 þ 0.12 nM for WT versus 0.82 þ 0.16 nM for M181A),
the e⁄ciency of photolabeling is signi¢cantly reduced (relative
Fig. 2. Speci¢c photolabeling of the rNK-1R with 125I-BH-Bpa8SP
and 125I-Bpa7NKA. Both 125I-BH-Bpa8SP and 125I-Bpa7NKA spe-
ci¢cally photolabel the same protein which migrates di¡usely at
MrV80 kDa on SDS^PAGE due to the heterogeneity of receptor
glycosylation [37].
Fig. 3. Tryptic digestion pattern of 125I-BH-Bpa8SP- and 125I-
Bpa7NKA-photolabeled rNK-1Rs. Tryptic digestion (0.02 mg/ml) of
125I-BH-Bpa8SP-labeled rNK-1R generates a major fragment at
MrV8 kDa in the absence of 30 mM DTT (3), which is reduced
in size to Mr V3 kDa in the presence of 30 mM DTT (+). An
identical tryptic digest pattern þ DTT is produced with 125I-
Bpa7NKA-labeled rNK-1R.
Fig. 4. Photoincorporation of 125I-BH-Bpa8SP and 125I-Bpa7NKA
into WT and mutant rNK-1Rs. The photoincorporation of 125I-BH-
Bpa8SP into the WT rNK-1R and M174A mutant rNK-1R is com-
parable; however, its photoincorporation into the M181A mutant
rNK-1R is markedly reduced. A similar pattern of receptor photoin-
corporation e⁄ciencies is reported when 125I-Bpa7NKA is the pho-
toligand. Importantly, the M181A and M174A mutant rNK-1Rs
display only slight di¡erences in their binding a⁄nity for the photo-
ligands as compared to WT rNK-1R; IC50 values are shown.
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percent photoincorporation of 100% for WT versus 36% for
M181A). However, when alanine is substituted for M174,
which is not the precise site of photoincorporation of 125I-
BH-Bpa8SP, there is only a modest e¡ect on binding a⁄nity
(IC50 values of 0.77 þ 0.12 nM for WT versus 0.39 þ 0.11 nM
for M174A) and only a small decrease in photolabeling e⁄-
ciency (relative percent photoincorporation of 100% for WT
versus 71% for M174A).
These two mutant receptors were also photolabeled with
125I-Bpa7NKA (Fig. 4), and the binding and photolabeling
results compared with those obtained with 125I-BH-Bpa8SP.
In parallel with the results seen with 125I-BH-Bpa8SP, (i) a
marked decrease in the e⁄ciency of photoincorporation of
125I-Bpa7NKA into the M181A mutant was observed (relative
percent photoincorporation of 100% for WT versus 28% for
M181A) and (ii) a comparable e⁄ciency of photoincorpora-
tion of 125I-Bpa7NKA into the M174A mutant was observed
(relative percent photoincorporation of 100% for WT versus
83% for M174A). Again, paralleling the results seen with 125I-
BH-Bpa8SP, the substitution of alanine for either M181 or
M174 had no marked e¡ect on 125I-Bpa7NKA binding a⁄nity
(Fig. 4). Taken together, these results provide strong evidence
that the site of 125I-Bpa7NKA covalent attachment to the
rNK-1R is the same as that of 125I-BH-Bpa8SP (i.e. E2 loop
residue M181) (Fig. 5). Interestingly, the mutant receptors in
which alanine was substituted for M174 and M181 display only
slight di¡erences in their binding a⁄nity for Bpa8SP and
Bpa7NKA, indicating that neither M174 nor M181 per se con-
tribute signi¢cantly to the total binding energy despite their
location at the ligand^receptor interface. These ¢ndings sug-
gest that several ligand^receptor contacts exist in the high-
a⁄nity binding complex, and are consistent with the view
that multiple peptide^receptor interactions participate in pep-
tide recognition and receptor activation.
4. Discussion
In this study, we (i) con¢rm published reports establishing
that NKA binds to the NK-1R with high a⁄nity [14,15] and
(ii) present the ¢rst data directly identifying a site of interac-
tion between NKA and the NK-1R at the bimolecular inter-
face. First, we demonstrate that 125I-Bpa7NKA is an e⁄cient
and speci¢c photoligand for the rNK-1R. Second, we restrict
the site of photoinsertion of 125I-Bpa7NKA to an amino acid
of the rNK-1R between residues 178 and 190 on the E2 loop.
As previously reported, this same restricted segment of the
rNK-1R contains M181, the site of 125I-BH-Bpa8SP photoin-
sertion as documented by MALDI mass spectrometry [19].
(iii) We show that a comparable loss of photoinsertion e⁄-
ciency results when either 125I-BH-Bpa8SP or 125I-Bpa7NKA
is used to photolabel a mutant rNK-1R in which the side-
chain of M181 has been removed. Taken together, these results
indicate that in the high-a⁄nity bound state, the equivalent
positions within the common C-terminal sequences of SP and
NKA are in close proximity to M181 on the E2 loop of the
rNK-1R.
In our laboratory, we have demonstrated that when the
side-chain of an identi¢ed contact residue of a photoligand
on a receptor is removed, a marked loss of photoincorpora-
tion results in the absence of a signi¢cant a¡ect on peptide
binding [26]. Pertinent to this investigation, we show that
when M181 of the rNK-1R is mutated to an alanine, the pho-
tolabeling e⁄ciency of 125I-BH-Bpa8SP is dramatically re-
duced. Since we had restricted the site of 125I-Bpa7NKA pho-
toinsertion to a region of the rNK-1R containing the site of
125I-BH-Bpa8SP covalent attachment (i.e. M181), we found it
plausible to speculate that both photoligands might have the
same contact residue, particularly since the photoreactive ami-
no acid of each ligand is in an equivalent position within the
conserved tachykinin C-terminal tail. Paralleling the results
obtained when 125I-BH-Bpa8SP is used to photolabel the
M181A mutant receptor, we in fact demonstrate a signi¢cant
loss of photoincorporation of 125I-Bpa7NKA into the M181A
mutant receptor, validating its contact site to the rNK-1R as
M181. Thus, the strategy of using speci¢cally mutated rNK-
1Rs and photoa⁄nity labeling experiments to characterize the
site of 125I-Bpa7NKA covalent attachment to the rNK-1R was
both novel and successful, and eliminated the necessity of
purifying the site of peptide^receptor interaction for analysis
by mass spectrometry.
It is important to note that the observation of two structur-
ally related peptides displaying di¡erences in their binding
a⁄nity for a given receptor target depending on the assay
used (i.e. homologous versus heterologous competition assays)
is not limited to SP and NKA interacting with the NK-1R,
but rather is emerging as a more general phenomenon for
other structurally related peptide families [27]. For example,
although vasoactive intestinal peptide (VIP) competes for the
binding of the structurally similar peptide pituitary adenylate
cyclase activating polypeptide (PACAP) to a receptor target
that has been designated the PACAP receptor (PACAP-R)
with low a⁄nity, in direct binding experiments radiolabeled
VIP is found to bind the PACAP-R with high a⁄nity [28].
Table 2
Binding a⁄nities of SP and NKA to WT, M174A and M181A rNK-1Rs
Receptor 125I-BH-SP binding versus unlabeled SP IC50
(nM þ S.E.M.)
125I-NKA binding versus unlabeled NKA IC50
(nM þ S.E.M.)
WT 0.9 þ 0.3 5.0 þ 2.0
M174A 1.4 þ 0.4 5.3 þ 2.1
M181A 1.5 þ 0.6 6.1 þ 2.4
Fig. 5. Schematic diagram of the ¢rst (E1) and second (E2) extracel-
lular loops of the rNK-1R. The residues shown in gray correspond
to the MrV3 kDa trypsin-generated rNK-1R fragment (residues
178^190). A disul¢de bond exists between C105 and C180, linking E1
and E2 near the membrane surface. The E2 loop residue Met181,
the direct site of 125I-BH-Bpa8SP and 125I-Bpa7NKA photoinsertion
to the rNK-1R, is shown in black. TM = transmembrane domain.
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The most straightforward explanation for the observation
that two ligands can interact at the same receptor with high
a⁄nity but not readily compete is that they each interact with
the receptor at distinct sites [27]. To address the issue as to
whether SP and NKA interact with the NK-1R at the same or
di¡erent sites, Wijkhuisen et al. recently followed a molecular
recognition theory to identify regions of the NK-1R whose
hydropathic pro¢les were opposed to that of the common
tachykinin C-terminal sequence, and then performed binding
experiments on receptors mutated in those particular regions
[29]. They subsequently reported the identi¢cation of an NK-
1R domain located at the distal end of the E2 loop that
interacts with the C-terminus of NKA but not of SP, suggest-
ing the existence of distinct binding sites on the receptor for
the C-terminal sequences of these two peptides. In the current
study, however, we have taken a direct approach to study the
tachykinin/NK-1R complex by comparing the site of 125I-
Bpa7NKA photoinsertion to the rNK-1R with that of the
well-studied corresponding photoreactive analogue of SP,
125I-BH-Bpa8SP. By reporting that both 125I-Bpa7NKA and
125I-BH-Bpa8SP photolabel the same residue on the rNK-1R,
we provide evidence against the existence of a distinct, NKA-
preferring binding site, and conclude that the equivalent posi-
tions of SP and NKA within the conserved tachykinin C-ter-
minal tail are in close proximity to M181 in the peptide/rNK-
1R complex.
An alternative and somewhat more complex possibility to
account for the apparent discrepancy in homologous versus
heterologous competition assay results is that the NK-1R ex-
ists in multiple peptide-selective conformations that not only
display di¡erences in their ligand speci¢cities [27], but also
potentially in their G-protein and e¡ector molecule interac-
tions and evoked physiological responses [30]. We favor this
multiple conformation theory. Particularly since SP and NKA
arise from the same gene and are often co-expressed and co-
released in regions of the central nervous system and periph-
ery without detectable NK-2 receptors [31^33], that both pep-
tides may stimulate peptide-speci¢c e¡ector responses through
functional interaction with the NK-1R may have important
physiological consequences.
Using the direct and e⁄cient methods of photochemistry,
combined with speci¢c receptor residue site-directed mutagen-
esis, we have demonstrated that the common C-terminal se-
quences of SP and NKA contact the same region of the NK-
1R. We furthermore predict that the divergent N-terminal
regions of these two peptides will interact with di¡erent re-
gions of the NK-1R. Extensive biochemical analysis of the
high-a⁄nity SP/rNK-1R complex has already been performed
[18,19,22,34^37]. These studies directly document the impor-
tance of both the extracellular N-terminus and the E2 loop of
the rNK-1R for peptide recognition, and support the view-
point that several ligand^receptor interactions participate in
binding and activation [38^40]. Just as multiple contacts exist
between SP and the NK-1R in the bound state, so too will
multiple interactions undoubtedly occur between NKA and
the NK-1R. By directly evaluating and comparing the tachy-
kinin/rNK-1R bimolecular interface using multiple photoreac-
tive SP and NKA derivatives, we can use a photoa⁄nity-scan-
ning approach to further investigate the existence of these
non-distinct peptide-preferring receptor conformations, and
determine which residue^residue contacts participate in the
molecular processes of peptide recognition and receptor acti-
vation.
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